Citadel Advisors’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-21,200
Closed -$22K 15758
2022
Q3
$22K Buy
21,200
+9,900
+88% +$22.6K ﹤0.01% 12048
2022
Q2
$21K Sell
11,300
-2,400
-18% -$5.83K ﹤0.01% 12399
2022
Q1
$49K Sell
13,700
-7,400
-35% -$36.3K ﹤0.01% 12808
2021
Q4
$182K Buy
21,100
+4,600
+28% +$29.3K ﹤0.01% 11993
2021
Q3
$125K Buy
+16,500
New +$139K ﹤0.01% 12600

Other funds holding LHDX

Citadel Advisors's LHDX Position: Q1 2022 in Review

Citadel Advisors sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2022, closing a stake of 35,544 shares — an estimated $175K sold.

Citadel Advisors first reported a position in LHDX in Q1 2021 and held it in 3 quarters. The position peaked at $391K in Q3 2021. 40 funds tracked by Wall St. Rank hold LHDX as of Q1 2022.

  • Citadel Advisors reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Citadel Advisors sold 35,544 Lucira Health, Inc. Common Stock shares in Q1 2022, an estimated $175K.
  • Citadel Advisors first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Citadel Advisors's Lucira Health, Inc. Common Stock position peaked at $391K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.